1. Home
  2. BANR vs URGN Comparison

BANR vs URGN Comparison

Compare BANR & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banner Corporation

BANR

Banner Corporation

HOLD

Current Price

$70.29

Market Cap

2.3B

Sector

Finance

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$40.97

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANR
URGN
Founded
1890
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
BANR
URGN
Price
$70.29
$40.97
Analyst Decision
Hold
Strong Buy
Analyst Count
4
7
Target Price
$70.00
$29.29
AVG Volume (30 Days)
424.7K
782.4K
Earning Date
04-22-2026
05-06-2026
Dividend Yield
3.14%
N/A
EPS Growth
15.57
N/A
EPS
1.60
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$0.73
$129.09
Revenue Next Year
$5.69
$70.96
P/E Ratio
$43.03
N/A
Revenue Growth
N/A
N/A
52 Week Low
$57.05
$15.86
52 Week High
$72.65
$43.93

Technical Indicators

Market Signals
Indicator
BANR
URGN
Relative Strength Index (RSI) 57.62 63.35
Support Level $62.97 $18.23
Resistance Level $72.65 N/A
Average True Range (ATR) 1.57 2.11
MACD -0.00 -0.05
Stochastic Oscillator 60.71 61.79

Price Performance

Historical Comparison
BANR
URGN

About BANR Banner Corporation

Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho, and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: